Mantle Cell Lymphoma

Test Your Knowledge

Quiz: What Monotherapy Shows Safety in R/R MCL?

11/11/2021

Which of the following monotherapies showed rapid and durable responses, an acceptable safety profile, and was generally well tolerated in BTK inhibitor-naïve patients with R/R MCL?

Which of the following...

11/11/2021

Oncology

News

Parsaclisib Monotherapy Well Tolerated in Patients With R/R MCL

11/11/2021

Parsaclisib monotherapy showed rapid and durable response, an acceptable safety profile, and was generally well tolerated in BTK inhibitor-naïve patients with R/R MCL; these data were presented at the 2021 ASH Annual Meeting.

Parsaclisib monotherapy showed...

11/11/2021

Oncology

Videos

Dr Tam Discusses Ibrutinib Therapy Plus Venetoclax for R/R MCL

12/07/2020

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, discusses highlights from, "Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study", presented...

Constantine Tam, MBBS (Hons),...

12/07/2020

Oncology

News

Acalabrutinib Demonstrates Efficacy and Safety in Relapsed/Refractory MCL

12/12/2018

Long-term response to acalabrutinib remained consistent with high efficacy and manageable safety in patients with relapsed or refractory MCL, according to results from a follow-up study.

Long-term response to...

12/12/2018

Oncology

Bortezomib Maintenance or Consolidation Posttransplant Improves Survival in MCL

12/11/2018

Induction chemotherapy followed by bortezomib maintenance or consolidation was efficacious and tolerable for patients with mantle cell lymphoma who underwent autologous stem cell transplant.

Induction chemotherapy followed...

12/11/2018

Oncology

Circulating Tumor DNA May Predict Outcomes in Mantle Cell Lymphoma

12/07/2018

Dynamic changes in circulating tumor DNA that occur very early during therapy may predict outcomes for patients with mantle cell lymphoma.

Dynamic changes in circulating...

12/07/2018

Oncology

Optimal Induction Chemo Identified for Transplant-Eligible MCL

11/30/2018

Induction therapy with rituximab/bendamustine and rituximab/cytarabine followed by ASCT resulted in high rates of durable remissions for patients with MCL, according to study data presented at ASH 2018.

Induction therapy with...

11/30/2018

Oncology